HBM HOLDINGS-B(02142): On February 7th, the company repurchased shares worth nearly 10 million Hong Kong dollars. The technology platform has further expanded to diverse application scenarios.

HBM HOLDINGS-B (02142) announced a share repurchase plan on the market, with a value not exceeding 40 million Hong Kong dollars, taking into consideration that the current trading price undervalues the company's intrinsic value and business prospects. On February 7, 2025, the company repurchased shares worth nearly 10 million Hong Kong dollars in the public market, setting a single-day repurchase record for listed biotechnology companies on the Hong Kong Stock Exchange in 2025. This rapid progress reflects the company's commitment to enhancing shareholder value and its confidence in the long-term growth prospects of the company. Depending on the applicable repurchase authorization available at the time, the company may further implement repurchase plans based on market conditions. In 2023 and 2024, the company has repurchased a total of 5.87 million shares, all of which have been canceled by the company. This will help enhance the overall value for the remaining shareholders. The company is committed to maximizing shareholder value. The company's executive director, CEO, founder, and Chairman of the board, Dr. Wang Jinsong, has increased his shareholding. According to Dr. Wang Jinsong, he is confident in the overall development prospects and potential growth of the group. The current trading price undervalues the company's intrinsic value and business prospects. Dr. Wang Jinsong does not rule out the possibility of further increasing his shareholding at the appropriate time. The increase in shareholding indicates that the management believes there is a disconnect between the current valuation and the company's intrinsic value. The company continues to demonstrate a strong financial position, with cash and cash equivalents totaling 1.425 billion Hong Kong dollars as of June 30, 2024. The company has also received prepayments from its collaboration with Candid Therapeutics. This strong financial foundation and cash reserves will support the company's future growth. As of the date of this announcement, the company has entered into multiple collaborations since December 2024, such as collaborations with Windward Bio on immunological diseases, Kodiak Sciences on ophthalmic diseases, Candid Therapeutics on next-generation T cell engagers, and Invetx on animal health. These collaborations signify the further expansion of the company's technology platform into diversified applications, demonstrating the scalability and broad application prospects of the company's technology platform.